Immediate Management: Reverse Warfarin and Consider Thrombolysis
In a patient on warfarin for mitral stenosis with atrial fibrillation who presents with acute ischemic stroke within the treatment window, you should immediately reverse the warfarin anticoagulation and proceed with IV alteplase (tPA) if the patient meets eligibility criteria after reversal.
Acute Phase Management Algorithm
Step 1: Immediate Assessment and Warfarin Reversal
- Check INR immediately upon presentation
- If INR ≥ 2.0 and patient is otherwise eligible for thrombolysis:
Step 2: Thrombolysis Decision
Once INR is corrected, proceed with IV alteplase (0.9 mg/kg; maximum 90 mg) if:
- Patient presents within 3 hours of clearly defined symptom onset 2, 3
- No contraindications exist after warfarin reversal
- No extensive hypodensity on CT 4
The 2018 AHA/ASA guidelines support thrombolysis in anticoagulated patients once coagulation parameters are normalized 3. The key is not to delay imaging or assessment—move rapidly through reversal to enable reperfusion therapy 5.
Step 3: Aspirin Administration
- Do NOT give aspirin within 24 hours of thrombolysis 1
- If thrombolysis is NOT given: administer aspirin 160-325 mg within 24-48 hours of stroke onset 2, 4
- This provides a small but meaningful benefit with reasonable safety 2
Timing of Anticoagulation Reinitiation
This is the critical decision point where stroke severity and hemorrhagic transformation risk must guide timing:
For Transient Ischemic Attack (TIA):
Restart anticoagulation immediately after the index event 6
For Ischemic Stroke:
The evidence strongly supports early reinitiation within 2-14 days, with recent data favoring even earlier timing (within 4 days) for most patients 6, 7, 8, 9:
- Low risk for hemorrhagic conversion: Consider starting 2-4 days after stroke 6, 7, 8
- High risk for hemorrhagic conversion (large infarct, severe stroke): Delay beyond 14 days may be reasonable to reduce ICH risk 6
Imaging-guided approach (based on recent evidence):
- Small to moderate infarcts: Initiate within 4 days 8, 9
- Large infarcts or severe stroke: Consider 6-7 days or longer 8
- Petechial hemorrhagic transformation (HI1/HI2): Early initiation still safe 8
- Parenchymal hematoma (PH1): Delay 6-7 days 8
- Parenchymal hematoma (PH2): Delay ≥4 weeks 8
Choice of Anticoagulant for Secondary Prevention
For this patient with mitral stenosis and AF, warfarin remains the recommended anticoagulant 6, 10, 11:
- Target INR 2.5 (range 2.0-3.0) for rheumatic mitral valve disease with AF 10, 11
- Direct oral anticoagulants (DOACs) are NOT recommended for moderate to severe mitral stenosis 6
- The INVICTUS trial showed VKA superiority over rivaroxaban in rheumatic heart disease 12
If this were non-valvular AF: DOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) would be preferred over warfarin 6
Critical Pitfalls to Avoid
Do not use heparin bridging in the acute period—parenteral anticoagulation within 48 hours increases hemorrhagic transformation risk 2, 4, 13
Do not add antiplatelet agents routinely to warfarin in patients with rheumatic mitral valve disease—this increases bleeding risk without clear benefit 10
Do not delay thrombolysis for prolonged reversal attempts—use rapid reversal agents (4F-PCC) rather than waiting for FFP to work 1
Do not restart anticoagulation too early in large strokes—hemorrhagic transformation risk peaks in the first 2 weeks, especially with extensive infarcts 13, 8
Do not use DOACs in this patient—mechanical valves and moderate-to-severe mitral stenosis are absolute contraindications to DOACs 14, 6
Monitoring Requirements
- Blood pressure control: Maintain <180/105 mmHg for at least 24 hours after thrombolysis 1
- Cardiac monitoring: At least 24 hours to screen for arrhythmias 1
- Serial neurological assessments to detect hemorrhagic transformation 2
- INR monitoring: Weekly during warfarin reinitiation, then monthly when stable 15, 14